Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALDX

Aldeyra Therapeutics Inc

Dec 01 • 04:00PM ET

2.86

Dollar change +0.09
Percentage change 3.25	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.78	Insider Own	3.96%	Shs Outstand	58.56M	Perf Week	13.04%
Market Cap	168.23M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	-54.20%	Shs Float	56.49M	Perf Month	12.60%
Income	-45.69M	PEG	-	EPS next Q	-0.21	Inst Own	59.37%	Short Float / Ratio	5.59% / 1.21	Perf Quarter	-62.22%
Sales	0.00M	P/S	-	EPS this Y	26.47%	Inst Trans	-1.12%	Short Interest	3.16M	Perf Half Y	-73.15%
Book/sh	2.08	P/B	1.38	EPS next Y	42.50%	ROA	-27.12%	Target Price	9.00	Perf Year	-48.93%
Cash/sh	2.44	P/C	1.17	EPS next 5Y	-	ROE	-32.04%	52W Range	1.42 - 11.97	Perf YTD	-58.91%
Dividend	-	P/FCF	-	EPS past 5Y	5.38%	ROI	-36.36%	52W High	-76.11%	Beta	1.40
Dividend %	-	Quick Ratio	6.67	Sales past 5Y	0.00%	Gross Margin	-	52W Low	101.41%	ATR	0.27
Employees	15	Current Ratio	6.67	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	51.98	Volatility	8.26% 10.87%
Optionable	Yes	Debt/Eq	0.13	EPS Q/Q	44.26%	Profit Margin	-	Rel Volume	0.35	Prev Close	2.77
Shortable	Yes	LT Debt/Eq	0.02	Earnings	Aug 03 AMC	Payout	-	Avg Volume	2.61M	Price	2.86
Recom	1.29	SMA20	13.29%	SMA50	-17.64%	SMA200	-60.72%	Volume	905,080	Change	3.25%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-27-22	Resumed	H.C. Wainwright	Buy	$15
Feb-08-21	Initiated	H.C. Wainwright	Buy	$26
Dec-16-20	Initiated	Berenberg	Buy	$32
Oct-30-20	Initiated	Jefferies	Buy	$24
Oct-16-20	Initiated	BTIG Research	Buy	$29
Sep-22-20	Initiated	Alliance Global Partners	Buy	$32
May-12-20	Initiated	Oppenheimer	Outperform	$12
Dec-04-18	Initiated	Citigroup	Buy	$23
Sep-26-18	Reiterated	Cantor Fitzgerald	Overweight	$23 → $30
Sep-13-18	Initiated	Janney	Buy
Jan-26-18	Initiated	Seaport Global Securities	Buy	$13
Sep-26-16	Initiated	H.C. Wainwright	Buy	$18
Jul-01-16	Initiated	Stifel	Buy	$16
Jul-01-15	Initiated	Canaccord Genuity	Buy	$16
Mar-25-15	Initiated	Chardan Capital Markets	Buy	$16
Mar-20-15	Reiterated	H.C. Wainwright	Buy	$13 → $14
Nov-18-14	Initiated	H.C. Wainwright	Buy	$13
Jun-19-14	Initiated	Aegis Capital	Buy	$35

Show Previous Ratings

Nov-27-23 04:07PM	Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Nov-01-23 10:34AM	Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today? (InvestorPlace) +48.54%
07:05AM	Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks) -5.98%
Oct-17-23 10:13AM	Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback (Zacks)
10:22AM	Loading…
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Jul-20-23 09:55AM	Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect? (Zacks)
Jul-06-23 07:00AM	Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum (Business Wire)
Jun-29-23 07:00AM	Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX2191 in Patients with Retinitis Pigmentosa (Business Wire)
05:20AM	The Petri Dish: Startup behind VR treatments gets $16M, Aldeyra notches midstage trial win (American City Business Journals)
Jun-28-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa (Business Wire)
Jun-27-23 12:03PM	Aldeyra Therapeutics' Chronic Cough Potential Shows Significant Reduction In Cough Frequency Versus Placebo (Benzinga)
07:00AM	Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX629 in Patients With Chronic Cough (Business Wire)
Jun-26-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX629 in Patients with Chronic Cough (Business Wire) +5.63%
Jun-23-23 07:00AM	Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes (Business Wire) -8.26%
09:34AM	Loading…
Jun-21-23 09:34AM	Aldeyra Therapeutics Provides Regulatory Update on ADX-2191 (Business Wire) -27.44%
Jun-16-23 10:26AM	Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study (Zacks)
Jun-15-23 02:52PM	Why Aldeyra Therapeutics Stock Is Trading Higher Today (Benzinga)
07:08AM	Aldeyra Therapeutics eye treatment meets late-stage study main goal (Reuters)
07:00AM	Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE2 Trial of Reproxalap in Allergic Conjunctivitis (Business Wire)
Jun-14-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE2 Trial in Allergic Conjunctivitis (Business Wire)
Jun-02-23 07:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (Business Wire)
May-07-23 07:30AM	This Biotech Is a Sight for Sore Eyes (TheStreet.com)
May-04-23 07:00AM	Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights (Business Wire)
Apr-13-23 07:00AM	Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis (Business Wire)
Apr-06-23 07:00AM	Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis (Business Wire)
Mar-30-23 07:00AM	Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough (Business Wire)
Mar-16-23 07:00AM	Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX2191 in Retinitis Pigmentosa (Business Wire)
Mar-11-23 02:59AM	Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 11:05PM	Q4 2022 Aldeyra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +7.19%
07:00AM	Loading…
07:00AM	Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (Business Wire)
Mar-02-23 07:00AM	FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma (Business Wire) +5.78%
Mar-01-23 07:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Feb-28-23 03:22PM	Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients (Benzinga) -5.06%
07:00AM	Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease (Business Wire)
Feb-23-23 07:00AM	Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy (Business Wire) +5.91%
Feb-22-23 05:26AM	Owning 40% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), (Simply Wall St.)
Feb-16-23 07:00AM	Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX629 Into New Phase 2 Systemic Disease Trials (Business Wire) +5.46%
Feb-09-23 07:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference (Business Wire)
Feb-07-23 07:00AM	Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease (Business Wire) +9.37%
Jan-12-23 06:37AM	Insiders made the right call by buying US$1.2m Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stock this year, currently sit on US$349k profit (Simply Wall St.) +7.29%
Dec-21-22 07:00AM	Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX2191 for the Treatment of Primary Vitreoretinal Lymphoma (Business Wire) +6.23%
Dec-13-22 01:37PM	Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication (Benzinga)
08:00AM	Aldeyra Therapeutics Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial (Business Wire)
Dec-01-22 08:00AM	Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA (Business Wire) +10.00%
Nov-29-22 08:00AM	Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease (Business Wire) +5.00%
Nov-10-22 07:00AM	Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights (Business Wire) +6.18%
Nov-03-22 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Nov-02-22 01:45PM	Aldeyra Therapeutics Is a Speculative Stock Worth a Small Position (TheStreet.com)
Oct-26-22 08:00AM	Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting (Business Wire) +7.81%
Oct-06-22 12:23PM	Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder (Benzinga)
07:00AM	Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy (Business Wire)
Oct-05-22 04:05PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy (Business Wire)
Sep-14-22 08:00AM	Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones (Business Wire)
Sep-07-22 08:00AM	Aldeyra Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Sep-01-22 06:56AM	Owning 48% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), (Simply Wall St.)
Aug-15-22 09:55AM	Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Aug-07-22 03:00AM	Aldeyra Therapeutics (ALDX) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-05-22 07:00AM	Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights (Business Wire) +10.90%
06:09AM	Joseph Edelman Just Bought 2.2% More Shares In Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Simply Wall St.)
Aug-01-22 02:55PM	Oppenheimer Says S&P 500 Could Rise Another 12% by Year-End and These Stocks Could Follow (TipRanks)
Jul-29-22 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Jul-13-22 10:53AM	Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals (Zacks)
Jul-12-22 09:00AM	Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial (Benzinga) +14.99%
07:00AM	Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial (Business Wire)
Jul-11-22 04:05PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap (Business Wire)
Jun-28-22 12:20PM	Trade Alert: The CEO, President & Director Of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), Todd Brady, Has Just Spent US$60k Buying 2.4% More Shares (Simply Wall St.)
Jun-21-22 11:01AM	Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way? (Simply Wall St.) -5.07%
Jun-09-22 08:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (Business Wire) +10.29%
Jun-08-22 09:40AM	Why Aldeyra Therapeutics' Shares Are Soaring Today? (Benzinga)
07:00AM	Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease (Business Wire)
Jun-07-22 04:05PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease (Business Wire) +12.15%
May-24-22 07:00AM	Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease (Business Wire)
May-23-22 04:05PM	Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference (Business Wire)
May-18-22 03:26PM	Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness (Benzinga) -6.82%
08:00AM	Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness (Business Wire)
May-05-22 08:30PM	Aldeyra Therapeutics (ALDX) Q1 2022 Earnings Call Transcript (Motley Fool) -5.12%
07:00AM	Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights (Business Wire)
May-04-22 08:30AM	Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting (Business Wire)
Apr-28-22 04:05PM	Aldeyra Therapeutics Announces Chief Financial Officer Transition (Business Wire) +8.31%
Apr-27-22 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Apr-21-22 08:00AM	Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (Business Wire)
Apr-05-22 08:00AM	Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease (Business Wire)
Mar-29-22 08:00AM	Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day (Business Wire)
Mar-22-22 08:00AM	Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022 (Business Wire)
Mar-18-22 07:30AM	Aldeyra Therapeutics (ALDX) Q4 2021 Earnings Call Transcript (Motley Fool)
Mar-17-22 07:00AM	Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights (Business Wire) +16.27%
Mar-14-22 08:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference (Business Wire) -8.54%
Mar-10-22 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2021 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Mar-08-22 08:00AM	Aldeyra Therapeutics Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis Pigmentosa (Business Wire) +8.80%
Mar-07-22 11:28AM	Could The Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ownership Structure Tell Us Something Useful? (Simply Wall St.) +7.14%
Feb-10-22 08:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference (Business Wire)
Feb-01-22 08:00AM	Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model (Business Wire)
Jan-18-22 01:38PM	HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ... (GuruFocus.com) -7.67%
Jan-11-22 08:00AM	Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra® (Business Wire)
Jan-07-22 01:38PM	Woodstock Corp Buys Amgen Inc, Applied Materials Inc, FedEx Corp, Sells Reata Pharmaceuticals ... (GuruFocus.com)
Jan-06-22 08:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference (Business Wire)
Jan-04-22 08:00AM	Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy (Business Wire)
Dec-29-21 10:18AM	Palatin (PTN) Begins Phase III Study For Dry Eye Disease (Zacks)
Dec-20-21 04:05PM	Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease (Business Wire)

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERCEPTIVE ADVISORS LLC	10% Owner	Oct 18	Sale	1.74	306,499	533,308	8,593,586	Oct 18 05:15 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Oct 16	Sale	1.60	2,450,000	3,920,000	8,900,085	Oct 18 05:15 PM
Brady Todd C	President and CEO	Sep 07	Option Exercise	0.55	273,058	150,728	1,728,343	Sep 11 05:42 PM
Phillips Gary M.	Director	Sep 07	Option Exercise	0.55	5,437	3,001	14,812	Sep 11 04:31 PM
Walker Neal	Director	Aug 22	Option Exercise	0.55	9,604	5,301	15,854	Aug 24 04:13 PM
Bronstein Ben	Director	Jun 27	Option Exercise	0.55	9,604	5,301	28,248	Jun 29 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALDX

Aldeyra Therapeutics Inc

Upgrade your FINVIZ experience